Header Logo

Connection

MOHIT KHERA to Testosterone

Back to Details
This is a "connection" page, showing publications MOHIT KHERA has written about Testosterone.
MOHIT KHERA
Connection Strength
17.735
Testosterone
  1. Impact of testosterone therapy and hypogonadism on treatment outcomes in Peyronie's disease: a multicenter retrospective analysis of collagenase clostridium histolyticum therapy. J Sex Med. 2026 Jun 05; 23(7).
    View in: PubMed
    Score: 0.657
  2. The interplay between testosterone and depression: bridging research, clinical applications, and health: a narrative review. Sex Med Rev. 2026 Apr 01; 14(2).
    View in: PubMed
    Score: 0.649
  3. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025 Oct 04; 13(4):548-573.
    View in: PubMed
    Score: 0.627
  4. Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study. J Sex Med. 2025 09 04; 22(9):1564-1571.
    View in: PubMed
    Score: 0.623
  5. Testosterone deficiency and treatments: common misconceptions and practical guidance for patient care. Sex Med Rev. 2025 Jul 03; 13(3):373-380.
    View in: PubMed
    Score: 0.616
  6. Testosterone replacement therapy in men on active surveillance for prostate cancer. J Sex Med. 2025 04 08; 22(3):432-438.
    View in: PubMed
    Score: 0.606
  7. Newer formulations of oral testosterone undecanoate: development and liver side effects. Sex Med Rev. 2025 Jan 31; 13(1):33-40.
    View in: PubMed
    Score: 0.598
  8. Hypogonadism management and cardiovascular health. Postgrad Med. 2020 Dec; 132(sup4):35-41.
    View in: PubMed
    Score: 0.445
  9. Controversies with testosterone therapy. Can J Urol. 2020 08; 27(S3):20-23.
    View in: PubMed
    Score: 0.438
  10. Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male. Eur Urol Focus. 2018 04; 4(3):321-323.
    View in: PubMed
    Score: 0.382
  11. The Role of Testosterone Therapy in the Setting of Prostate Cancer. Curr Urol Rep. 2018 Jun 30; 19(8):67.
    View in: PubMed
    Score: 0.379
  12. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. J Sex Med. 2018 02; 15(2):148-158.
    View in: PubMed
    Score: 0.368
  13. Hypogonadism: Therapeutic Risks, Benefits, and Outcomes. Med Clin North Am. 2018 Mar; 102(2):361-372.
    View in: PubMed
    Score: 0.364
  14. Alternatives to Testosterone Therapy: A Review. Sex Med Rev. 2018 01; 6(1):106-113.
    View in: PubMed
    Score: 0.364
  15. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017 Nov; 27(6):511-515.
    View in: PubMed
    Score: 0.362
  16. Testosterone inhibits the growth of prostate cancer xenografts in nude mice. BMC Cancer. 2017 Sep 07; 17(1):635.
    View in: PubMed
    Score: 0.358
  17. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM?2015). J Sex Med. 2016 12; 13(12):1787-1804.
    View in: PubMed
    Score: 0.340
  18. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016 07; 91(7):908-26.
    View in: PubMed
    Score: 0.329
  19. Testosterone Therapies. Urol Clin North Am. 2016 May; 43(2):185-93.
    View in: PubMed
    Score: 0.323
  20. Male hormones and men's quality of life. Curr Opin Urol. 2016 Mar; 26(2):152-7.
    View in: PubMed
    Score: 0.322
  21. Testosterone is Protective against Cardiac Disease: Pro. J Urol. 2016 04; 195(4 Pt 1):831-2.
    View in: PubMed
    Score: 0.320
  22. Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer. Asian J Androl. 2015 Sep-Oct; 17(5):807-10.
    View in: PubMed
    Score: 0.311
  23. Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. J Urol. 2015 Nov; 194(5):1271-6.
    View in: PubMed
    Score: 0.306
  24. Controversies in testosterone supplementation therapy. Asian J Androl. 2015 Mar-Apr; 17(2):175-6.
    View in: PubMed
    Score: 0.301
  25. RE: Testosterone treatment is a potent tumor promoter for the rat prostate. Endocrinology. 2015 Jan; 156(1):L1-2.
    View in: PubMed
    Score: 0.297
  26. Reply to Julia Klap and Kevin R. Loughlin's letter to the editor re: Mohit Khera, David Crawford, Alvaro Morales, Andrea Salonia, Abraham Morgentaler. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115-23. Eur Urol. 2014 Aug; 66(2):e33.
    View in: PubMed
    Score: 0.284
  27. Controversies in the treatment of male hypogonadism. Urology. 2014 Apr; 83(4):957.
    View in: PubMed
    Score: 0.282
  28. Patients with testosterone deficit syndrome and depression. Arch Esp Urol. 2013 Sep; 66(7):729-36.
    View in: PubMed
    Score: 0.271
  29. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014 Jan; 65(1):115-23.
    View in: PubMed
    Score: 0.270
  30. 12-month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med. 2013 Mar; 125(2):8-18.
    View in: PubMed
    Score: 0.262
  31. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013 Aug; 190(2):639-44.
    View in: PubMed
    Score: 0.261
  32. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med. 2013 Feb; 10(2):562-9.
    View in: PubMed
    Score: 0.255
  33. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. J Androl. 2012 Sep-Oct; 33(5):927-37.
    View in: PubMed
    Score: 0.245
  34. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012 Mar; 15(1):14-21.
    View in: PubMed
    Score: 0.240
  35. Subcutaneous implantable testosterone pellets overcome noncompliance in adolescents with Klinefelter syndrome. J Androl. 2012 Jul-Aug; 33(4):570-3.
    View in: PubMed
    Score: 0.237
  36. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011 Nov; 8(11):3204-13.
    View in: PubMed
    Score: 0.235
  37. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011 Sep; 186(3):1005-11.
    View in: PubMed
    Score: 0.234
  38. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011 Apr; 185(4):1256-60.
    View in: PubMed
    Score: 0.228
  39. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr; 6(4):1165-1170.
    View in: PubMed
    Score: 0.197
  40. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009 Mar; 6 Suppl 3:234-8.
    View in: PubMed
    Score: 0.197
  41. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am. 2007 Nov; 34(4):549-53, vi.
    View in: PubMed
    Score: 0.181
  42. Testosterone Therapy in Adult Males with Hypogonadism. Eur Urol. 2026 Jul; 90(1):32-43.
    View in: PubMed
    Score: 0.159
  43. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology. 2025 05; 13(4):882-893.
    View in: PubMed
    Score: 0.146
  44. Changes in post-transplant serum testosterone levels in men undergoing lung transplantation: a pilot study using the TriNetX Research Network. Int J Impot Res. 2025 Aug; 37(8):595-600.
    View in: PubMed
    Score: 0.143
  45. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
    View in: PubMed
    Score: 0.138
  46. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 07 13; 389(2):107-117.
    View in: PubMed
    Score: 0.134
  47. Testosterone replacement therapy and cardiovascular disease. Int J Impot Res. 2022 Nov; 34(7):685-690.
    View in: PubMed
    Score: 0.121
  48. Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100?mg IM weekly or 200?mg IM biweekly. Int J Impot Res. 2022 Sep; 34(6):558-563.
    View in: PubMed
    Score: 0.117
  49. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. J Cardiovasc Pharmacol Ther. 2021 11; 26(6):630-637.
    View in: PubMed
    Score: 0.117
  50. Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men. Cancer Prev Res (Phila). 2021 07; 14(7):719-728.
    View in: PubMed
    Score: 0.115
  51. Testosterone's Role in COVID-19. J Sex Med. 2021 05; 18(5):843-848.
    View in: PubMed
    Score: 0.114
  52. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk. J Sex Med. 2021 01; 18(1):83-98.
    View in: PubMed
    Score: 0.112
  53. Controversies in Testosterone Therapy. Sex Med Rev. 2021 01; 9(1):149-159.
    View in: PubMed
    Score: 0.112
  54. A Critique of the AUA Guidelines on Testosterone Deficiency. J Sex Med. 2020 04; 17(4):561-564.
    View in: PubMed
    Score: 0.105
  55. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database. Clin Endocrinol (Oxf). 2019 12; 91(6):885-891.
    View in: PubMed
    Score: 0.103
  56. Caffeine intake is not associated with serum testosterone levels in adult men: cross-sectional findings from the NHANES 1999-2004 and 2011-2012. Aging Male. 2019 Mar; 22(1):45-54.
    View in: PubMed
    Score: 0.094
  57. The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. Clin Endocrinol (Oxf). 2018 07; 89(1):3-10.
    View in: PubMed
    Score: 0.093
  58. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population. J Sex Med. 2017 01; 14(1):88-97.
    View in: PubMed
    Score: 0.085
  59. Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction. J Sex Med. 2016 08; 13(8):1183-98.
    View in: PubMed
    Score: 0.083
  60. The nanochannel delivery system for constant testosterone replacement therapy. J Sex Med. 2015 Jun; 12(6):1375-80.
    View in: PubMed
    Score: 0.076
  61. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015 Feb; 90(2):224-51.
    View in: PubMed
    Score: 0.075
  62. Delivering enhanced testosterone replacement therapy through nanochannels. Adv Healthc Mater. 2015 Feb 18; 4(3):446-51.
    View in: PubMed
    Score: 0.073
  63. The safety of testosterone supplementation therapy in prostate cancer. Nat Rev Urol. 2014 Sep; 11(9):526-30.
    View in: PubMed
    Score: 0.072
  64. Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014 Jul; 11(7):1636-45.
    View in: PubMed
    Score: 0.071
  65. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry. Postgrad Med. 2013 Mar; 125(2):19-29.
    View in: PubMed
    Score: 0.065
  66. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging. 2012; 7:321-30.
    View in: PubMed
    Score: 0.063
  67. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med. 2012 May; 13(5):688-98.
    View in: PubMed
    Score: 0.062
  68. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(?)) insertion. J Sex Med. 2012 Feb; 9(2):594-601.
    View in: PubMed
    Score: 0.061
  69. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011 May; 123(3):17-27.
    View in: PubMed
    Score: 0.058
  70. Androgen replacement therapy after prostate cancer treatment. Curr Urol Rep. 2010 Nov; 11(6):393-9.
    View in: PubMed
    Score: 0.056
  71. Exploring the link between muscle quality and erectile dysfunction: assessing the impact of mass and strength. Sex Med Rev. 2025 Oct 04; 13(4):643-651.
    View in: PubMed
    Score: 0.039
  72. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 01 18; 109(2):569-580.
    View in: PubMed
    Score: 0.035
  73. Oral testosterone therapy: past, present, and future. Sex Med Rev. 2023 04 03; 11(2):124-138.
    View in: PubMed
    Score: 0.033
  74. Joint association of statins and testosterone replacement therapy with cardiovascular disease among older men with prostate cancer: SEER-Medicare 2007-2015. Cancer Epidemiol. 2022 08; 79:102172.
    View in: PubMed
    Score: 0.031
  75. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022 05; 10(4):669-676.
    View in: PubMed
    Score: 0.030
  76. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 03; 245:41-50.
    View in: PubMed
    Score: 0.030
  77. The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer. Cancer Causes Control. 2021 Sep; 32(9):965-976.
    View in: PubMed
    Score: 0.029
  78. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature. Sex Med Rev. 2021 07; 9(3):393-405.
    View in: PubMed
    Score: 0.028
  79. Is treatment of hypogonadism safe for men after a solid organ transplant? Results from a retrospective controlled cohort study. Int J Impot Res. 2022 Jan; 34(1):50-54.
    View in: PubMed
    Score: 0.028
  80. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019 May 30; 5(1):38.
    View in: PubMed
    Score: 0.025
  81. Diagnosing secondary hypogonadism: important consequences for fertility and reversibility. BJU Int. 2016 Apr; 117(4):552-4.
    View in: PubMed
    Score: 0.020
  82. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med. 2014 Nov; 11(11):2764-71.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.